HCVguidelines.org — a website developed by the American Association of the Study for Liver Diseases and the Infectious Diseases Society of America to provide up-to-date guidance on the treatment of hepatitis C — has added to its guidance and resources for the diagnosis and treatment of hepatitis C.

New additions to the website include a primer on HCV resistance, guidance on treating people who have undergone kidney transplantation, and guidance on HCV in pregnant women and children. Additionally, the entire guidance has been updated to reflect recent approvals of glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir.

“HCVguidelines.org is a valuable resource for researchers, clinicians, health professionals and the broader hepatology and infectious disease communities,” say panel co-chairs Raymond T. Chung, MD; Arthur Y. Kim, MD; Susanna Naggie, MD; and Hugo E. Vargas, MD. “As new HCV therapies become available, and additional resources are needed to navigate diagnosis and treatment, our panel remains focused on ensuring complete, high-quality and timely guidance.”

The new sections of Guidance include:

  • HCV Resistance Primer: Provides key information including terminology, guidance on when and when not to provide resistance testing, approaches to overcoming resistance, and several other topics.
  • Kidney Transplant Patients: Includes guidance for use of DAA therapy in patients who have undergone kidney transplant.
  • HCV in Pregnancy: Includes recommendations for testing, treating, and monitoring pregnant women with HVC as well as a section on key postpartum issues.

·        HCV in Children: Includes recommendations for testing children, as well as information for counseling parents on transmission and prevention and monitoring and medical treatment.